𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma : Feasibility and clinical outcome

✍ Scribed by Sarmad Sadeghi; Laurence Albiges; Laura S. Wood; Shari L. Black; Timothy D. Gilligan; Robert Dreicer; Jorge A. Garcia; Bernard J. Escudier; Brian I. Rini

Book ID
112066991
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
172 KB
Volume
118
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical factors associated with outcome
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
✍ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to